Comparative Pharmacology
Head-to-head clinical analysis: BECLOVENT versus VANCERIL DOUBLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BECLOVENT versus VANCERIL DOUBLE STRENGTH.
BECLOVENT vs VANCERIL DOUBLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway hyperresponsiveness, and suppresses immune cell activity.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, adhesion molecule expression, and eosinophil survival, thereby reducing airway inflammation.
2 inhalations (84 mcg) twice daily; not to exceed 10 inhalations (420 mcg) per day. Administered via oral inhalation using a metered-dose inhaler.
2 inhalations (168 mcg beclomethasone dipropionate) twice daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life of beclomethasone dipropionate is 0.5 hours; active metabolite beclomethasone-17-monopropionate has half-life of 2.7 hours; clinically, systemic effects persist for 12-24 hours.
Terminal elimination half-life: 1.5–2 hours for beclomethasone dipropionate; 2.7 hours for active metabolite beclomethasone-17-monopropionate. Clinical context: supports twice-daily dosing.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (60-70%) and urine (10-15%); less than 5% unchanged drug in urine.
Primarily hepatic metabolism; metabolites excreted renally (~90% as free and conjugated metabolites) and fecally (<10%).
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid